Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
Information source: Duke University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Carcinoma, Non-Small-Cell Lung
Intervention: Dasatinib (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: Duke University Official(s) and/or principal investigator(s): Neal Ready, M.D., Principal Investigator, Affiliation: Duke University
Summary
Src expression has been identified in a majority of Non-Small Cell Lung Cancer (NSCLC) cell
lines and there is preclinical evidence that Src family kinases may be important in hypoxic
growth and angiogenesis in NSCLC. We hypothesize that the inhibition of Src pathway with
dasatinib will demonstrate anti-tumor activity in early stage NSCLC, with a tolerable safety
profile.
Patients will receive dasatinib, a Src inhibitor, for 3 weeks prior to surgical resection
for early stage NSCLC. Fresh frozen tumor tissue is needed for genomic analysis. If fresh
frozen tumor tissue is not available from the initial diagnosis, a biopsy will be required
to participate in this trial. A second tumor sample will be obtained at time of surgical
resection to evaluate for changes in genomic expression profiles.
Patients will be eligible to receive 3 months of adjuvant dasatinib therapy after completion
of standard adjuvant therapy or after recovery from surgery if no standard adjuvant therapy
is given, if there is evidence of neoadjuvant tumor response (radiologic and/or pathologic)
to dasatinib.
Many patients who present with NSCLC are active smokers. Patients who are smoking up until
the time of their surgery experience increased peri-operative complications compared to
patients who have not smoked cigarettes immediately prior to surgery. While this trial will
not be limited to active smokers, the period of smoking cessation prior to surgery is an
attractive window of opportunity during which the potentially active novel anticancer
therapy dasatinib can be offered to the patient.
Clinical Details
Official title: Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC).
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Response Rate
Secondary outcome: Safety and Tolerability of Neoadjuvant DasatinibGene Expression Profile Activation of Src Pathways Safety and Tolerability of Adjuvant Dasatinib
Detailed description:
This is a phase II study of dasatinib, a targeted biologic agent, known to inhibit Src. It
is difficult to assess outcome in phase II adjuvant trials because there is no measurable
disease to evaluate efficacy and there are many variables that could confound comparing
survival of subjects on trial to historical controls. Therefore, after a fresh frozen tumor
tissue sample is obtained for genomic analysis, we plan to treat subjects with neoadjuvant
dasatinib and then measure tumor response to therapy prior to surgery. Resected tumor will
also be assessed for pathologic response as well as for changes in genomic expression
patterns.
Subjects will be treated with neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks, with a
mandatory minimum of 3 days (72 hours) off of study drug prior to surgical resection.
Imaging studies will be done pre-treatment and pre-surgery to assess radiologic response to
therapy. The surgical specimen will be evaluated for pathologic response. A tumor tissue
sample will be obtained from the surgical specimen for genomic analysis and will be
evaluated for changes in genomic expression profiles.
Patients whose tumors have a response to neoadjuvant dasatinib therapy might benefit with
better cancer control if they receive a potentially therapeutic course of adjuvant
dasatinib. Patients that have at least a 15% decrease or better objective response, without
evidence of progression to neoadjuvant dasatinib (per tumor evaluation pre-surgery) or
pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant
dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after
the completion of standard adjuvant therapy or after recovery from surgery if no standard
adjuvant therapy is given. Patients will be followed for approximately 30 days after the
last dose of dasatinib to assess toxicity.
Response will be evaluated in Src regulated and Src deregulated cohorts of tumors. If
responses to neoadjuvant dasatinib occur, then accrual to either or both cohorts will be
expanded. If there are no responses to neoadjuvant dasatinib in the cohort groups, then
accrual to either or both cohorts will be stopped. The results of this study may be useful
in designing future studies in early stage NSCLC using dasatinib alone or in combination
with chemotherapy.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Suspected or histological/cytological diagnosis of Non-Small Cell Lung Cancer
(NSCLC), Stage IB (≥4 cm per CT) or Stage IIA or IIB, amenable to surgical resection
- Must be deemed a surgical candidate
- Tumors ≥2 cm in maximum diameter without radiographic, bronchoscopic or pathologic
evidence of nodal metastases are eligible for biopsy
- Fresh tissue biopsy material must be available for genomics analysis prior to
initiating dasatinib therapy
- Age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- No prior chemotherapy, immunotherapy, radiation therapy or biologic/targeted therapy
for any malignancy
- Adequate Organ Function:
- Total bilirubin
- Hepatic enzymes (AST, ALT) ≤2. 5x institutional ULN
- Serum creatinine <1. 5x institutional ULN
- Hemoglobin ≥9 gm/dL
- Neutrophil count (ANC or AGC) ≥1500 per μL
- Platelets ≥100,000 per μL
- Prothrombin time (PT)/a partial thromboplastin time (PTT) ≤1. 5x control
- No other serious medical or psychiatric illness
- Ability to take oral medication (dasatinib must be swallowed whole)
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
preferably within 72 hours and no later than 7 days, prior to the start of study drug
administration
- Both sexually active males and females of reproductive potential must agree to use an
adequate method of contraception throughout treatment and for at least 4 weeks after
study drug is stopped
- Signed written informed consent including Health Insurance Portability and
Accountability Act (HIPAA) according to institutional guidelines
Exclusion Criteria:
- Previous or concomitant malignancy in the past 2 years other than curatively treated
carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin
- Prior dasatinib therapy
- Evidence of pleural or pericardial effusion of any grade
- Cardiac Symptoms:
- Uncontrolled angina, congestive heart failure (CHF), or myocardial infarction
(MI) within 6 months
- Diagnosed congenital long QT syndrome
- Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes)
- Prolonged QT corrected (QTc) interval on pre-entry EKG (>450 msec)
- Uncontrolled hypertension defined as >160/90 on a regimen of antihypertensive
therapy
- Subjects with hypokalemia or hypomagnesaemia if it cannot be corrected
- History of diagnosed congenital acquired bleeding disorders (e. g., von Willebrand's
disease)
- Ongoing or recent (≤3 months) significant (≥grade 3) gastrointestinal bleeding
- Concomitant Medications:
- Drugs that are generally accepted to have a risk of causing Torsades de Pointes
including: (Patients must discontinue drug 7 days prior to starting dasatinib)
**quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide,
dofetilide, erythromycin, clarithromycin, chlorpromazine, haloperidol,
mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol,
methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl,
pentamidine, sparfloxacin, lidoflazine
- Current therapeutic dose heparin or coumadin therapy
- St. John's Wort and all herbal supplements must be stopped while on dasatinib
- IV bisphosphonates will be withheld for 2 weeks prior and 6 weeks after
dasatinib administration due to risk of hypocalcaemia
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (e. g., infectious) illness
- Pregnant or breastfeeding
- Active or uncontrolled infection requiring intravenous antibiotics
- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of dasatinib (e. g., ulcerative diseases, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- Patients who have received investigational drugs ≤4 weeks prior to starting study
drug and/or who have not recovered from side effects of such therapy
Locations and Contacts
Duke University Medical Center, Durham, North Carolina 27710, United States
Additional Information
Duke Institute for Genome Sciences and Policy
Related publications: Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006 Nov;12(11):1294-300. Epub 2006 Oct 22. Erratum in: Nat Med. 2008 Aug;14(8):889. Nat Med. 2007 Nov;13(11):1388. Retraction in: Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Nat Med. 2011 Jan;17(1):135. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006 Aug 10;355(6):570-80. Erratum in: N Engl J Med. 2007 Jan 11;356(2):201-2. Retraction in: Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. N Engl J Med. 2011 Mar 24;364(12):1176. Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D'Amico M, Pestell RG, West M, Nevins JR. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet. 2003 Jun;34(2):226-30.
Starting date: November 2007
Last updated: January 27, 2015
|